SAB Biotherapeutics, Inc. (SABS), Monday announced its partnership with Naval Medical Research Centre to develop a therapy, named SAB-176, which can be used as a pre- and post-exposure prophylactic treatment for influenza type A and type B.
Influenza is a highly contagious infection of respiratory passages caused by a virus.
Under the Cooperative Research and Development Agreement, both the parties will conduct a pharmacokinetic, safety and tolerability study of the therapy.
The company has utilized its proprietary DiversitAb platform to manufacture SAB-176, fully human polyclonal antibodies targeting influenza from Transchromosomic Bovine.
Last year, the U.S. Food and Drug Administration had granted Breakthrough Therapy and Fast Track Designations to SAB-176 based on the positive outcome from the clinical proof-of-concept Phase 2 study in an influenza challenge model with intravenous formulation.
Currently, SAB's stock is sliding 4.81 percent, to $4.645 on the Nasdaq.
For comments and feedback: editorial@rttnews.com